Society of Urologic Oncology Annual Meeting (SUO)

The novel androgen receptor-signaling inhibitor led to negative repeat biopsies after 90 days of treatment among men with very-low risk to favorable intermediate risk prostate cancer on active surveillance.

A study from the 21st Annual Meeting of the Society of Urologic Oncology concluded that active surveillance is a safe management strategy for patients with small renal masses suspicious for renal cell carcinoma.

Enzalutamide improved progression-free survival and increased time to prostate-specific antigen progression, compared with bicalutamide, in patients with nonmetastatic castration-resistant prostate cancer.

A phase 1 trial showed that treatment with neoadjuvant nivolumab was tolerable in patients with nonmetastatic high-risk clear cell renal cell carcinoma.

The efficacy of the novel intravesical gene-mediated therapy nadofaragene firadenovec was sustained across subgroups of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.

Research presented at the 21st Annual Meeting of the Society of Urologic Oncology found organized telehealth systems effectively lessened the impact of the coronavirus disease 2019 pandemic on appointment cancellations.

Researchers utilized the Seamless MD app to aid in ERAS protocols for patients undergoing radical cystectomy, while mitigating risks from in-person visits during the COVID-19 pandemic.

This study found that radiation therapy may provide some benefit for patients with high-risk non–muscle invasive bladder cancer, though the quality of evidence in this current setting is low.

A telemedicine Multidisciplinary Urologic Cancer Clinic at the University of Washington/Seattle Cancer Care Alliance conducted video visits, inducing high patient satisfaction, sparing substantial travel burden and providing individuals access to multidisciplinary urologic cancer care.

A pooled analysis compared survival among patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy and either targeted therapy or immunotherapy regimens utilizing checkpoint inhibitors.

Research suggested oncologists may recommend specific timeframes in which cystectomy should be performed to avoid unnecessary mortality due to delays.

Researchers sought to better understand the impact of treatment on intimate relationships for patients with bladder cancer.